Athersys shares rebound somewhat since falling by two-thirds on clinical trial results


Athersys plans to ask shareholders to approve a reverse stock split of its shares.

Previous Raleigh pharma with acquire-and-develop strategy launches clinical trial
Next Three Triad businesses receive NC building reuse grants that could create almost 100 jobs